Vertex Pharmaceuticals Inc
VRTX462.130USD
+5.260+1.15%
Cierre 08/01, 16:00（ET）Cotizaciones retrasadas 15 min
118.75BCap. mercado
PérdidaP/E TTM
Más Datos de Vertex Pharmaceuticals Inc Compañía
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Información de la empresa
Símbolo de cotizaciónVRTX
Nombre de la empresaVertex Pharmaceuticals Inc
Fecha de salida a bolsaJul 24, 1991
Fundada en1989
Director ejecutivoDr. Reshma Kewalramani
Número de empleados6100
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 24
Dirección50 Northern Avenue
CiudadBOSTON
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02210
Teléfono16173416393
Sitio Webhttps://www.vrtx.com/
Símbolo de cotizaciónVRTX
Fecha de salida a bolsaJul 24, 1991
Fundada en1989
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
41.81K
+38.72%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
40.00K
--
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.67K
+40.46%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
30.30K
+19.95%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
24.47K
--
Mr. Jonathan Biller, J.D.
Mr. Jonathan Biller, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
17.61K
+5.74%
Mr. Duncan Mckechnie
Mr. Duncan Mckechnie
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
16.13K
--
Mr. Lloyd A. Carney
Mr. Lloyd A. Carney
Independent Director
Independent Director
7.12K
+12.60%
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Independent Director
Independent Director
4.83K
+8.93%
Ms. Jennifer J. Schneider
Ms. Jennifer J. Schneider
Independent Director
Independent Director
1.72K
+86.33%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
41.81K
+38.72%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
40.00K
--
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.67K
+40.46%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
30.30K
+19.95%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
24.47K
--
Mr. Jonathan Biller, J.D.
Mr. Jonathan Biller, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
17.61K
+5.74%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por negocioUSD
Nombre
Ganancia
Proporción
TRIKAFTA
2.54B
91.86%
Other product revenues
156.60M
5.67%
ALYFTREK
53.90M
1.95%
CASGEVY
14.20M
0.51%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
1.65B
59.91%
Europe
826.60M
29.95%
Other
280.10M
10.15%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
TRIKAFTA
2.54B
91.86%
Other product revenues
156.60M
5.67%
ALYFTREK
53.90M
1.95%
CASGEVY
14.20M
0.51%
Estadísticas de accionistas
Actualizado: jue., 15 de may
Actualizado: jue., 15 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Capital World Investors
11.11%
The Vanguard Group, Inc.
9.10%
Capital Research Global Investors
5.66%
BlackRock Institutional Trust Company, N.A.
5.45%
State Street Global Advisors (US)
4.59%
Other
64.08%
Accionistas
Accionistas
Proporción
Capital World Investors
11.11%
The Vanguard Group, Inc.
9.10%
Capital Research Global Investors
5.66%
BlackRock Institutional Trust Company, N.A.
5.45%
State Street Global Advisors (US)
4.59%
Other
64.08%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
59.72%
Investment Advisor/Hedge Fund
28.09%
Research Firm
2.55%
Pension Fund
2.35%
Bank and Trust
2.04%
Sovereign Wealth Fund
1.44%
Hedge Fund
1.29%
Insurance Company
0.16%
Individual Investor
0.14%
Other
2.22%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
2926
251.46M
97.92%
+1.75M
2025Q1
2977
252.24M
98.22%
-39.54K
2024Q4
2877
248.76M
96.87%
-2.25M
2024Q3
2786
247.87M
96.18%
-4.19M
2024Q2
2747
248.36M
96.27%
-4.14M
2024Q1
2680
247.63M
95.87%
-4.48M
2023Q4
2608
247.92M
96.20%
-4.51M
2023Q3
2477
248.64M
96.45%
-6.19M
2023Q2
2488
248.89M
96.55%
-7.11M
2023Q1
2468
250.11M
97.13%
-4.74M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Capital World Investors
28.53M
11.11%
+207.61K
+0.73%
Mar 31, 2025
The Vanguard Group, Inc.
23.38M
9.1%
+232.41K
+1.00%
Mar 31, 2025
Capital Research Global Investors
14.54M
5.66%
+4.11M
+39.38%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
14.00M
5.45%
-330.35K
-2.31%
Mar 31, 2025
State Street Global Advisors (US)
11.79M
4.59%
-190.75K
-1.59%
Mar 31, 2025
Fidelity Management & Research Company LLC
7.62M
2.97%
-1.49M
-16.32%
Mar 31, 2025
Jennison Associates LLC
5.06M
1.97%
+744.68K
+17.25%
Mar 31, 2025
Geode Capital Management, L.L.C.
5.76M
2.24%
+113.52K
+2.01%
Mar 31, 2025
Wellington Management Company, LLP
5.45M
2.12%
-461.34K
-7.80%
Mar 31, 2025
Invesco Capital Management (QQQ Trust)
5.31M
2.07%
-20.76K
-0.39%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: hace 29 minutos
Actualizado: hace 29 minutos
Nombre
Proporción
VanEck Biotech ETF
10.59%
Tema Neuroscience and Mental Health ETF
10.48%
ProShares Ultra Nasdaq Biotechnology
7.77%
Invesco Nasdaq Biotechnology ETF
7.77%
iShares Biotechnology ETF
6.83%
Invesco Biotechnology & Genome ETF
4.86%
Natixis Loomis Sayles Focused Growth ETF
4.46%
Franklin Genomic Advancements ETF
4.34%
Global X Genomics & Biotechnology ETF
3.55%
Tema Heart & Health ETF
3.25%
Ver más
VanEck Biotech ETF
Proporción10.59%
Tema Neuroscience and Mental Health ETF
Proporción10.48%
ProShares Ultra Nasdaq Biotechnology
Proporción7.77%
Invesco Nasdaq Biotechnology ETF
Proporción7.77%
iShares Biotechnology ETF
Proporción6.83%
Invesco Biotechnology & Genome ETF
Proporción4.86%
Natixis Loomis Sayles Focused Growth ETF
Proporción4.46%
Franklin Genomic Advancements ETF
Proporción4.34%
Global X Genomics & Biotechnology ETF
Proporción3.55%
Tema Heart & Health ETF
Proporción3.25%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
